Antibody–drug conjugates in urothelial carcinoma: scientometric analysis and clinical trials analysis

Antibody–drug conjugates in urothelial carcinoma: scientometric analysis and clinical trials analysis

In 2020, bladder cancer, which commonly presents as urothelial carcinoma, became the 10th most common malignancy. For patients with metastatic urothelial carcinoma, the standard first-line treatment remains platinum-based chemotherapy, with immunotherapy serving as an alternative in cases of program...

Full description

Bibliographic Details
Main Authors: Meng Zhang, Yuanye Zuo, Siyi Chen, Yaonan Li, Yang Xing, Lei Yang, Hong Wang, Rui Guo
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-03-01
Series:Frontiers in Oncology
Subjects:
scientometric analysis
clinical trials
urothelial carcinoma
antibody-drug conjugates
EV
SG
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1323366/full

Similar Items

Similar Items